+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer



Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer



International Journal of Radiation Oncology, Biology, Physics 72(4): 967-971



To evaluate the efficacy and adverse effects of image-guided stereotactic body radiation therapy (SBRT) in centrally/superiorly located non-small-cell lung cancer (NSCLC). We delivered SBRT to 27 patients, 13 with Stage I and 14 with isolated recurrent NSCLC. A central/superior location was defined as being within 2 cm of the bronchial tree, major vessels, esophagus, heart, trachea, pericardium, brachial plexus, or vertebral body, but 1 cm away from the spinal canal. All patients underwent four-dimensional computed tomography-based planning, and daily computed tomography-on-rail guided SBRT. The prescribed dose of 40 Gy (n = 7) to the planning target volume was escalated to 50 Gy (n = 20) in 4 consecutive days. With a median follow-up of 17 months (range, 6-40 months), the crude local control at the treated site was 100% using 50 Gy. However, 3 of 7 patients had local recurrences when treated using 40 Gy. Of the patients with Stage I disease, 1 (7.7%) and 2 (15.4%) developed mediastinal lymph node metastasis and distant metastases, respectively. Of the patients with recurrent disease, 3 (21.4%) and 5 (35.7%) developed mediastinal lymph node metastasis and distant metastasis, respectively. Four patients (28.6%) with recurrent disease but none with Stage I disease developed Grade 2 pneumonitis. Three patients (11.1%) developed Grade 2-3 dermatitis and chest wall pain. One patient developed brachial plexus neuropathy. No esophagitis was noted in any patient. Image-guided SBRT using 50 Gy delivered in four fractions is feasible and resulted in excellent local control.

(PDF emailed within 0-6 h: $19.90)

Accession: 055922942

Download citation: RISBibTeXText

PMID: 18954709

DOI: 10.1016/j.ijrobp.2008.08.001


Related references

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 80(4): 1015-1022, 2011

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer: in regards to Register et al. Int J Radiat Oncol Biol Phys 2011;80:1015-1022. International Journal of Radiation Oncology, Biology, Physics 82(1): 492; Author Reply 492, 2012

Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). International Journal of Clinical Oncology 22(5): 849-856, 2017

Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases. International Journal of Radiation Oncology, Biology, Physics 81(3): 856-862, 2011

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". International Journal of Radiation Oncology, Biology, Physics 88(5): 1120-1128, 2014

Stereotactic Body Radiation Therapy (SBRT) For Centrally Located Primary and Recurrent Non-Small Cell Lung Cancer: Analysis of Toxicity and Local Control. International Journal of Radiation Oncology*biology*physics 93(3): E418-E419, 2015

Clinical Outcome and Toxicity in Central Located Stage I or Isolated Recurrent Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology*biology*physics 87(2): S514-S515, 2013

Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer. Translational Lung Cancer Research 8(1): 58-69, 2019

The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases. Frontiers in Oncology 4: 151, 2014

Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*biology*physics 94(1): 5-6, 2016

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Radiation Oncology 10: 113, 2016

Stereotactic ablative radiation therapy for centrally located recurrences of non-small cell lung cancer: in regard to Chang et al. International Journal of Radiation Oncology, Biology, Physics 89(5): 1141-1142, 2014

Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 21(5): 413-418, 2018

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 101(3): 558-563, 2018

Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. Journal of Thoracic Oncology 10(4): 577-585, 2015